Monthly
US$200
Billed every month
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 3 applicationsNo longer listed under review: 1 application
Current coverage may be incomplete
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Loaded records: 0 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 0 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | ||||||
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
Loaded records: 10 distinct approval numbers and 10 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 合肥远志医药科技开发有限公司 | 国药准字H20265271 | 10ml:1g | Not stated by source | XA02ADL183X002010185197 | NHSA |
| 太康海恩药业有限公司 | 国药准字H20253652 | 10ml:1g | Not stated by source | XA02ADL183X002010103172 | NHSA |
| 重庆中创科医药有限公司 | 国药准字H20254454 | 10ml:1g | Not stated by source | XA02ADL183X002010183891 | NHSA |
| 广西百会医药科技有限公司 | 国药准字H20255206 | 10ml:1g | Not stated by source | XA02ADL183X002010185214 | NHSA |
| 太康海恩药业有限公司 | 国药准字H20253652 | 10ml:1g | Not stated by source | XA02ADL183X002010203172 | NHSA |
| 重庆中创科医药有限公司 | 国药准字H20254454 | 10ml:1g | Not stated by source | XA02ADL183X002010283891 | NHSA |
| 广西百会医药科技有限公司 | 国药准字H20255206 | 10ml:1g | Not stated by source | XA02ADL183X002010285214 | NHSA |
| 太康海恩药业有限公司 | 国药准字H20253652 | 10ml:1g | Not stated by source | XA02ADL183X002010303172 | NHSA |
| 广西百会医药科技有限公司 | 国药准字H20255206 | 10ml:1g | Not stated by source | XA02ADL183X002010385214 | NHSA |
| 太康海恩药业有限公司 | 国药准字H20253652 | 10ml:1g | Not stated by source | XA02ADL183X002010403172 | NHSA |
| 广西百会医药科技有限公司 | 国药准字H20255206 | 10ml:1g | Not stated by source | XA02ADL183X002010485214 | NHSA |
| 太康海恩药业有限公司 | 国药准字H20253652 | 10ml:1g | Not stated by source | XA02ADL183X002010503172 | NHSA |
| 广西百会医药科技有限公司 | 国药准字H20255206 | 10ml:1g | Not stated by source | XA02ADL183X002010585214 | NHSA |
| 太康海恩药业有限公司 | 国药准字H20253652 | 10ml:1g | Not stated by source | XA02ADL183X002010603172 | NHSA |
| 广西百会医药科技有限公司 | 国药准字H20255206 | 10ml:1g | Not stated by source | XA02ADL183X002010685214 | NHSA |
| 太康海恩药业有限公司 | 国药准字H20253652 | 10ml:1g | Not stated by source | XA02ADL183X002010703172 | NHSA |
| 广西百会医药科技有限公司 | 国药准字H20255206 | 10ml:1g | Not stated by source | XA02ADL183X002010785214 | NHSA |
| 太康海恩药业有限公司 | 国药准字H20253652 | 10ml:1g | Not stated by source | XA02ADL183X002010803172 | NHSA |
| 广西百会医药科技有限公司 | 国药准字H20255206 | 10ml:1g | Not stated by source | XA02ADL183X002010885214 | NHSA |
| 太康海恩药业有限公司 | 国药准字H20253652 | 10ml:1g | Not stated by source | XA02ADL183X002010903172 | NHSA |
| 广西百会医药科技有限公司 | 国药准字H20255206 | 10ml:1g | Not stated by source | XA02ADL183X002010985214 | NHSA |
| 太康海恩药业有限公司 | 国药准字H20253652 | 10ml:1g | Not stated by source | XA02ADL183X002011003172 | NHSA |
| 广西百会医药科技有限公司 | 国药准字H20255206 | 10ml:1g | Not stated by source | XA02ADL183X002011085214 | NHSA |
| 广西百会医药科技有限公司 | 国药准字H20255206 | 10ml:1g | Not stated by source | XA02ADL183X002011185214 | NHSA |
| 杭州民生健康药业股份有限公司 | 国药准字H20243983 | 10ml:1g | Not stated by source | XA02ADL183X002010100500 | NHSA |
| 四川益生智同医药生物科技发展有限公司 | 国药准字H20243135 | 10ml: 1g | Not stated by source | XA02ADL183X002010102087 | NHSA |
| 黑龙江中桂制药有限公司 | 国药准字H20244898 | 10ml:1g | Not stated by source | XA02ADL183X002010103804 | NHSA |
| 广西南宁百会药业集团有限公司 | 国药准字H10960261 | 200ml:20g | Not stated by source | XA02ADL183X002010105122 | NHSA |
| 四川益生智同医药生物科技发展有限公司 | 国药准字H20243135 | 10ml: 1g | Not stated by source | XA02ADL183X002010184204 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20243522 | 10ml:1g | Not stated by source | XA02ADL183X002010184221 | NHSA |
| 浙江寰领医药科技有限公司 | 国药准字H20243782 | 10ml:1g | Not stated by source | XA02ADL183X002010184239 | NHSA |
| 杭州民生健康药业股份有限公司 | 国药准字H20243983 | 10ml:1g | Not stated by source | XA02ADL183X002010200500 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20243522 | 10ml:1g | Not stated by source | XA02ADL183X002010284221 | NHSA |
| 浙江寰领医药科技有限公司 | 国药准字H20243782 | 10ml:1g | Not stated by source | XA02ADL183X002010284239 | NHSA |
| 杭州民生健康药业股份有限公司 | 国药准字H20243983 | 10ml:1g | Not stated by source | XA02ADL183X002010300500 | NHSA |
| 浙江高跖医药科技股份有限公司 | 国药准字H20243522 | 10ml:1g | Not stated by source | XA02ADL183X002010384221 | NHSA |
| 浙江寰领医药科技有限公司 | 国药准字H20243782 | 10ml:1g | Not stated by source | XA02ADL183X002010384239 | NHSA |
| 杭州民生健康药业股份有限公司 | 国药准字H20243983 | 10ml:1g | Not stated by source | XA02ADL183X002010400500 | NHSA |
| 浙江寰领医药科技有限公司 | 国药准字H20243782 | 10ml:1g | Not stated by source | XA02ADL183X002010484239 | NHSA |
| 杭州民生健康药业股份有限公司 | 国药准字H20243983 | 10ml:1g | Not stated by source | XA02ADL183X002010500500 | NHSA |
| 浙江寰领医药科技有限公司 | 国药准字H20243782 | 10ml:1g | Not stated by source | XA02ADL183X002010584239 | NHSA |
| 杭州民生健康药业股份有限公司 | 国药准字H20243983 | 10ml:1g | Not stated by source | XA02ADL183X002010600500 | NHSA |
| 浙江寰领医药科技有限公司 | 国药准字H20243782 | 10ml:1g | Not stated by source | XA02ADL183X002010684239 | NHSA |
| 浙江寰领医药科技有限公司 | 国药准字H20243782 | 10ml:1g | Not stated by source | XA02ADL183X002010784239 | NHSA |
| 浙江寰领医药科技有限公司 | 国药准字H20243782 | 10ml:1g | Not stated by source | XA02ADL183X002010884239 | NHSA |
| 广西南宁百会药业集团有限公司 | 国药准字H10960261 | 200ml:20g | Not stated by source | XA02ADL183X002020105122 | NHSA |
| 广西南宁百会药业集团有限公司 | 国药准字H10960261 | 200ml:20g | Not stated by source | XA02ADL183X002030105122 | NHSA |
| 广西南宁百会药业集团有限公司 | 国药准字H10960261 | 200ml:20g | Not stated by source | XA02ADL183X002030205122 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Loaded records: 9 filings and 9 distinct first applicants.
Generic 8 · Supplement 1
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 江苏晨牌邦德药业有限公司 | CYHS2601578 | Generic | 2026/07/03 | Not stated by source | CDE |
| 漯河市汇创医药有限公司;安徽永生堂药业有限责任公司 | CYHB2601847 | Supplement | 2026/10/09 | Not stated by source | CDE |
| 重庆世森医药科技有限公司;陕西汉江药业集团股份有限公司 | CYHS2602427 | Generic | 2026/09/29 | Not stated by source | CDE |
| 浙江核力欣健药业有限公司 | CYHS2602348 | Generic | 2026/09/20 | Not stated by source | CDE |
| 吉林省博采众科生物医药有限公司;吉林省博大伟业制药有限公司 | CYHS2601441 | Generic | 2026/06/17 | Not stated by source | CDE |
| 安徽康融药业有限公司 | CYHS2600606 | Generic | 2026/03/02 | Not stated by source | CDE |
| 华润三九医药股份有限公司;华润三九(唐山)药业有限公司 | CYHS2504146 | Generic | 2025/12/03 | Not stated by source | CDE |
| 浙江领创优品药业有限公司;浙江赛默制药有限公司 | CYHS2501860 | Generic | 2025/05/23 | Not stated by source | CDE |
| 安徽皓誉生物制药有限公司;安徽永生堂药业有限责任公司 | CYHS2501057 | Generic | 2025/03/14 | Not stated by source | CDE |
Loaded records: 5 filings and 5 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 江苏晨牌邦德药业有限公司 | CYHS2601578 | Generic | 2026/07/03 | Not stated by source | CDE |
| 重庆世森医药科技有限公司;陕西汉江药业集团股份有限公司 | CYHS2602427 | Generic | 2026/09/29 | Not stated by source | CDE |
| 浙江核力欣健药业有限公司 | CYHS2602348 | Generic | 2026/09/20 | Not stated by source | CDE |
| 吉林省博采众科生物医药有限公司;吉林省博大伟业制药有限公司 | CYHS2601441 | Generic | 2026/06/17 | Not stated by source | CDE |
| 安徽康融药业有限公司 | CYHS2600606 | Generic | 2026/03/02 | Not stated by source | CDE |
Non-component matches: 9 companies with A status and 1 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 铝碳酸镁 | 河南优凯制药有限公司 | Y20260000343 | I | Exact ingredient | 2026/05/11 | CDE |
| 铝碳酸镁 | 湖北欧立制药有限公司 | Y20190006540 | A | Exact ingredient | 2026/06/17 | CDE |
| 铝碳酸镁 | 河南精康制药有限公司 | Y20220000638 | A | Exact ingredient | 2025/01/18 | CDE |
| 铝碳酸镁 | 湖南九典宏阳制药有限公司 | Y20190021360 | A | Exact ingredient | 2025/07/28 | CDE |
| 铝碳酸镁 | 重庆华森制药股份有限公司 | Y20190009445 | A | Exact ingredient | 2024/10/09 | CDE |
| 铝碳酸镁 | Kyowa Chemical Industry Co.,Ltd. | Y20190009046 | A | Exact ingredient | 2024/12/13 | CDE |
| 铝碳酸镁 | 广西南宁百会药业集团有限公司 | Y20190004208 | A | Exact ingredient | 2025/01/03 | CDE |
| 铝碳酸镁 | 安丘市鲁安药业有限责任公司 | Y20190002189 | A | Exact ingredient | 2025/04/30 | CDE |
| 铝碳酸镁 | 台山市新宁制药有限公司 | Y20190001700 | A | Exact ingredient | 2026/02/27 | CDE |
| 铝碳酸镁 | Kyowa Chemical Industry Co., Ltd. | Y20190000289 | A | Exact ingredient | 2025/12/13 | CDE |
| 铝碳酸镁 | 重庆华森制药股份有限公司 | Y20180001477 | A | Exact ingredient | 2024/06/21 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
CYHS2501173
Fact date: 2026/10/27 · Site observation date: 2026/10/27
Accepted: 2025/03/25
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗CYHB2601847
Fact date: 2026/10/09 · Site observation date: 2026/10/22
View source ↗CYHS2602427
Fact date: 2026/09/29 · Site observation date: 2026/10/22
View source ↗Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
US$200
Billed every month
US$540
Billed every three months
US$180 per month
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy